) mice ( Figure 1 ).
The human Ikkα gene is located at 10q24.31, close to Pten (10q23). Many studies have suggested that alterations within the 10q22-10q26 region may be involved in human SCC development. IKKα downregulation and Ikkα mutations and deletions have been reported in various types of human SCCs. A point mutation-mediated IKKα deletion has been identified in a lethal human syndrome, in which multiple organs are malformed [5] . Chemical carcinogen treatment induces Ikkα mutations and deletions in mouse skin SCCs [1] . These findings underscore the importance of IKKα in the pathogenesis of these human diseases.
Lung cancer is the leading cause of cancer mortality worldwide. Lung SCC, one of major types of lung cancers, is strongly associated with smoking that contains carcinogens. Smoking can also act as an inflammatory irritator. It is thought that SCCs, frequently found in the upper and central regions of the lungs, are derived from the basal cells (a type of squamous epithelial cell) of the pseudostratified epithelial layer of bronchi; whereas adenocarcinomas (ADCs) are derived from the epithelial cells of alveoli. Many molecular alterations, such as deregulated EGFR, PIK3CA, p53, Rb, and c-Myc, have been identified in human lung SCCs, but mice overexpressing or lacking these genes do not well recapitulate the development of lung SCCs, although a proportion of K-ras G12D ;Lkb1 -/-mice develop mixed SCCs and ADCs in the lungs [4, 6] .
Biomarkers of increased p63, Trim29, and keratin 5 (K5) are used to distinguish human lung SCCs from ADCs. We also have demonstrated increased p63, Trim29, and K5 levels, deregulated RhoV, CDK1, IGF, ROS1, c-Myc, p53, Rb, and LKB1 expression, and
Figure 1: IKKα downregulation dysregulates the expression of multiple oncogenes and tumor suppressors in K5
+ lung epithelial cells. The [4, 7] , suggesting that some similar molecular mechanisms may be involved in the pathogenesis of skin and lung SCCs in these different IKKα mutant mice.
Previously, we showed that IKKα inactivation interrupts early hematopoietic cell development, resulting in increased myeloid cells in Ikkα KA/KA mice [8] . We further demonstrated that these increased macrophages are necessary for promoting lung SCC formation in L-Ikkα KA/ KA mice by increasing DNA damage to deregulate tumor suppressors, oncogenes, and stem cell regulators ( Figure  1 ) [4] . We detected markedly increased macrophages, T cells, and multiple mediators in L-Ikkα KA/KA lungs compared to wild-type lungs. NF-κB activity is increased in CD45
-cells isolated from L-Ikkα KA/KA lungs as well as in a cell line derived from the L-Ikkα KA/KA lung SCC [4] . The increased NF-κB activity may contribute to multiple elevated mediator products and anti-apoptotic activities in lung epithelial cells. Importantly, we detected increased macrophages, and reduced IKKα levels in human lung SCCs and their adjacent lung tissues, indicating that IKKα reduction may not only promote lung epithelial cell malignant transformation, but also enhance inflammatory responses.
We have identified similar multi-molecular alterations in mouse and human lung SCCs [4] . Our immediate goal is to identify specific molecules, cells, or pathways that can be targeted for therapy, which will benefit human cancer patients. Using this model, we will investigate conditions for lung SCC metastasis and essential pulmonary inflammatory cell development, as well as the relationship between lung SCC and ADC pathogenesis.
